Transaction in Own Shares

SHIRE PLC - Transaction in Own Shares

PR Newswire

London, December 10

Transaction in Own Shares

December 11, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"),announces that in accordance with the authority granted by shareholders at theCompany's Annual General Meeting on April 24, 2012 it purchased 121,277 of itsordinary shares of 5 pence each ("Ordinary Shares") on December 10, 2012through both direct purchases of Ordinary Shares and through the purchase ofOrdinary Shares underlying ADRs. The highest and lowest price paid for thedirectly acquired Ordinary Shares was 1916.00 pence per share and 1888.00 penceper share respectively and for those Ordinary Shares acquired though thepurchase of ADRs was 3078.00 cents per share and 3069.00 cents per sharerespectively.

The purchased shares will be held as treasury shares. Following the abovepurchase, the Company holds 2,684,652 Ordinary Shares as treasury shares andhas 559,860,425 Ordinary Shares in issue (excluding treasury shares).

The purchases were made by an independent third party which makes its tradingdecisions independently of, and uninfluenced by the Company. The independenceof the third party enables the Company to continue to purchase Ordinary Shares(including Ordinary Shares underlying ADRs) during close periods and otherprohibited periods, should they arise. The third party has been appointed bythe Company to make purchases to December 31, 2013.

On December 4, 2012 the Company announced that it had purchased 61,222 OrdinaryShares on December 3, 2012. Due to a reporting error by the independent thirdparty, the announcement understated the actual number of Ordinary Sharespurchased by 100 Ordinary Shares. The correct number of Ordinary Sharespurchased on December 3, 2012 was 61,322 Ordinary Shares.

For further information please contact:

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and providehealthcare in the areas of:

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value forpatients, physicians, policymakers, payors and our shareholders.

www.shire.com